Axial spondyloarthritis

Updated treatment recommendations have been issued for ankylosing spondylitis and non-radiographic axial spondyloarthritis. There are 86 recommendations. In this slideshow, we highlight those categorized as "strongly recommended." 

Lilly has announced that it received FDA approval for Taltz (ixekizumab) for the treatment of active ankylosing spondylitis (radiographic axial spondyloarthritis).

The new approval represents the third time the FDA approved the injection treatments for adults.

A new set of guidelines has been released by the American College of Rheumatology, Spondylitis Association of America and the Spondyloarthritis Research and Treatment Network are offering guidance to physicians on treating axial spondyloarthritis.

An Indian-made biosimilar to adalimumab has been shown to be safe and effective for up to 24 weeks in patients with ankylosing spondylitis, say researchers writing in ACR Open Rheumatology this month.

Bone erosion, fat in joint spaces (backfill), and ankylosis visible on MRI could help identify women with axial spondyloarthritis, investigators wrote in a research article published last month in Arthritis & Rheumatology.

The established criteria for radiographic axial spondyloarthritis and axial spondyloarthritis that is classified as ankylosing spondylitis-is essentially the same, report physicians who recommend the interchangeable use of the terms "ankylosing spondylitis" and "radiographic axial spondyloarthritis."

New research shows that a newly identified species of gut bacteria is significantly depleted in patients with ankylosing spondylitis.

High levels of comorbidity burden are associated independently with poor physical function and increased disability in patients with psoriatic arthritis, however, patients ankylosing spondylitis did not report worse function when comorbidities were present.

In an effort to determine what causes immune mediated diseases such as ankylosing spondylitis, inflammatory bowel disease and psoriasis, researchers have focused on learning more about genetic pathogenic pathways responsible for autoimmunity. In this article, we review the data and highlight best practices.

A new study of long-term data demonstrates that infliximab and golimumab are both effective, safe treatments for symptoms of ankylosing spondylitis.

In a recent edition of Frontiers in Immunology, Dr. Walter Maksymowych, University of Alberta, reviews the use of biomarkers for diagnosis and prognosis in axial spondyloarthritis. Learn more in this summary.

Children affected by juvenile idiopathic arthritis, manifesting as non-systemic polyarthritis, sacroilitis or enthesitis, have a number of therapeutic options available. In this article, we outline the options.

Axial spondyloarthritis (axSpA) is never a straightforward diagnosis. In this slideshow, we highlight 11 disease manifestations associated with axSpA.

Delays in diagnosing axSpA are troubling, write the authors of a report in the journal Rheumatology. Delays of up to 10 years have been reported. Not all physicians may be familiar with the signs and symptoms of axSpA.

Physiotherapy, exercise and pain medications should be part of the treatment plan to improve the quality of life of patients suffering from stiffness associated with axial spondyloarthritis.

The cause of discovertebral lesions in ankylosing spondylitis may be due to infectious, inflammatory or traumatic etiologies suggest researchers writing in the Journal of Rheumatology. They examined the most prevalent-and conflicting-theories associated with this medical mystery.

A recent study suggests that the appearance of hidradenitis suppurativa may be another associated manifestation that can predict a more severe course of axial spondyloarthritis.

A recent study published in the Annals of the Rheumatic Diseases shows that ankylosing spondylitis is linked to an increased risk for venous thromboembolism and deep vein thrombosis.

Smoking in axial spondyloarthritis doesn't appear to impact treatment with TNF inhibitors despite the status of disease severity, a study shows.

Lack of trust in physicians, lack of information about biologics, medicine substitutions and the search for alternative therapies are among the reasons patients turn to the internet, a new study shows.

A well-established treatment for psoriasis, psoriatic arthritis, and Crohn’s disease failed to work in axial spondyloarthritis patients, a study shows. But the study's failure may tell us more than not.

Researchers writing in PLOS One report that patients with ankylosing spondylitis have a significant higher prevalence of dementia and Alzheimer’s dementia than the general population.

Half of patients with axial spondyloarthritis have both the axial and peripheral forms of the disease, which may explain why these patients have higher disease activity, researchers write in RMD Open.